Abstract:
A modified Saccharomyces cerevisiae cell, wherein the cell expresses minK but does not express TRK1 and TRK2. Also disclosed is a process for detecting modulators of minK, which comprises (a) treating such modified Saccharomyces cerevisiae cells with a test compound, (b) assessing growth in the presence of a test compound and (c) determining an increase or decrease in potassium uptake into the Saccharomyces cerevisiae cells. MinK inhibitors are useful anti-arrhythmic or antifibrillatory agents; activators, anti-ischemic agents.

Description:
FIELD OF THE INVENTION 
     This invention relates to yeast, recombinant DNA techniques, and to processes for detecting inhibitors and/or activators of potassium channels. 
     BACKGROUND OF THE INVENTION 
     The uptake of potassium ions in yeast cells occurs primarily through two specific proteins--a high and a low affinity potassium ion transporter. Rodriguez-Navarro and Ramos, J. Bacteriol, 159:940-945 (1984); Gaber, Styles, and Fink, Mol. Cell Biol. 8:2848-2859 (1988); Ko and Gaber, Genetics 125: 305-312 (1990). Two genes, designated TRK1 and TRK2 (for transporter of K) encode the high and low affinity transporters, respectively. Yeast strains that contain mutations in TRK1 and TRK2 exhibit a growth defect on media with minimal potassium ion (K + ) concentrations. In comparison to wild-type strains, which grow on media with as little as 5 μM potassium ion, transporter mutant strains require media supplemented with 100 mM potassium ion. Two laboratories used such deficient strains to isolate foreign plant genes that complement the growth defect on potassium-deficient media. Anderson, et al., Proc. Natl. Acad. Sci. U.S.A. 89: 3736-3740 (1992); Sentenac, et al., Science 256: 663-666 (1992). 
     In other species, a number of potassium channels have been cloned by molecular biological techniques. Many of these cloned channels are voltage-dependent potassium ion channels related to the Drosophila shaker channel. Several others are novel potassium ion channels. Hille, Ionic Channels of Excitable Membranes (1992); Strong et al., Mol. Biol. Evol. 10: 221-242 (1993). 
     One such newly discovered channel is the minK, or I sk , or IK s , channel, which has only 129-130 amino acids. Murai et al., Bioch. Biophys. Res. Comm. 161: 176-181 (1989); Swanson et al., Sem. Neurosci. 5: 117-124 (1993). A recent report indicates that residues 41 to 72 define the pore of the protein and are sufficient to form channels in lipid bilayers. Ben-Efraim et al., Biochemistry 32: 2371-2377 (1993). The channel minK displays very slow activation and inactivation kinetics. Philipson and Miller, TIPS 13:8-11 (1992). It is expressed in a number of tissues, including kidney, uterus and heart and in a number of species including humans. Swanson et al., Sem. Neurosci. 5: 117-124 (1993); Freeman and Kass, Biophysical J. 64: 342 (abstract) (1993). 
     Of considerable interest is the role of minK in the heart. It was known that ventricular cells have a repolarzing current, called the delayed rectifier. Recent evidence suggests that the delayed rectifier has two components: a rapid, rectifying component, I Kr , and a slow component, I Ks . Sanguinetti and Jurkiewicz, J. Gen Physiol. 96:195-215 (1990). I Kr  is blocked by such Class III antiarrhythmics as d-sotalol, dofetilide, and clofilium; I Ks , in contrast, is blocked by clofilium but not by d-sotalol or dofetilide. Honore et al., EMBO J. 10:2805-2811 (1990); Jurkiewicz and Sanguinetti, Circ. Res. 72: 75-83 (1993). When expressed in Xenopus oocytes, minK exhibits kinetics and pharmacology similar to those of I Ks  found in isolated myocytes, including blockage by clofilium. Honore et al., EMBO J. 10:2805-2811 (1991 ); Adelman, personal communication. Immunological detection of minK protein in cells possessing I Ks  has recently been reported. Freeman and Kass, Biophys. J. 64:342 (abstract) (1993). These results suggest that the minK product is the slow component of the delayed rectifier. 
     At faster heart rates, I Ks  contributes to the shortening of the action potential observed at rapid heart rates. Jurkiewicz and Sanguinetti, Circ. Res. 72: 75-83 (1993). Thus, a specific inhibitor of the minK channel would be an effective antifibrillatory or anti-arrhythmic agent. Activators of the minK channel, on the other hand, may be anti-ischemic agents. A need exists, therefore, for methods of screening for inhibitors and/or activators of the minK channel. 
     BRIEF DESCRIPTION OF THE INVENTION 
     The present invention concerns a modified Saccharomyces cerevisiae cell, wherein the cell expresses a nucleic acid sequence for a minK protein or a functional derivative or mutant thereof but does not express TRK1 and TRK2. 
     The present invention further concerns a process for detecting modulators of the minK channel, which comprises: 
     (a) treating modified Saccharomyces cerevisiae cells with a test substance, wherein the modified Saccharomyces cerevisiae cells express a nucleic acid sequence for a minK protein or a functional derivative or mutant thereof, but do not express TRK1 and TRK2; 
     (b) detecting any change in growth of the cells after treatment with the test substance. 
     This process is useful for detecting modulators of the minK channel. 
    
    
     BRIEF DESCRIPTION OF THE FIGURES 
     FIG. 1 shows representations of genomic fragments containing the wld type TRK1 and TRK2 loci and the corresponding mutant alleles, trk1::HIS3 and trk2::TRP1. The TRK1 and TRK2 coding regions are indicated by solid lines. The mutant alleles were transformed into a yeast strain to replace the wild type loci. 
     FIG. 2 shows the nucleotide (SEQ. ID. NO. 1) and deduced amino acid (SEQ. ID. NO. 2) sequences for TRK1. (Sequence reprinted from Murai et al., Bioch. Biophys. Res. Comm. 161: 176-181 (1989), which is incorporated herein by reference). Residues 41 to 72, which define the pore of the protein, are underlined. 
     FIG. 3 shows the nucleotide (SEQ. ID. NO. 3) and deduced amino acid sequence (SEQ. ID. NO. 4) sequences for TRK2. (Sequence reprinted from Gaber et al., Mol. Cell. Biol. 8: 2848-2859 (1988), which is incorporated herein by reference.) In the preferred embodiment described hereinafter, the portion underlined was deleted and replaced by marker gene HIS3. 
     FIG. 4 shows the nucleotide (SEQ. ID. NO. 5) and deduced amino acid (SEQ. ID. NO. 6) sequences for human minK. (Sequence reprinted from Ko and Gaber, Mol. Cell. Biol. 11: 4266-4273 (1991), which is incorporated herein by reference.) In the preferred embodiment described hereinafter, the portion underlined was deleted and replaced by marker gene TRP1. 
     FIG. 5 shows that growth of transporter mutant strains is potassium-dependent. Tetratype segregants from a cross between MATα trk1::HIS3×MATa trk2::TRP1 were patched onto rich media supplemented with 100 mM KC1. After overnight incubation at 30° C., the plate was replica-printed containg 100 mM, 10 mM or 0.1 mM KC1. Plates were incubated at 30° C. and scored for 48 hours. WT denotes wildtype, Low Aff.- denotes trk2 mutant, High Aff.- denotes trk1 mutant, High and Low denotes trk1, trk2 double mutant. 
     FIG. 6 shows cultures of strains containing the pGAL::HminK plasmid or the pGAL::TRK1 plasmid grown in inducing media (2% galactose) at 30° C. with vigorous aeration. Inhibitors were added to cultures over a range of concentrations. Samples were removed at various intervals and the optical density at 600 nm was determined. Growth measurements were normalized to values obtained for growth in the absence of drug and are plotted as relative growth versus concentration of drug. 
     FIG. 7A shows cultures of strains containing the pGAL vector, pGAL::TRK1 or the pGAL::HminK plasmid grown in inducing media (2% galactose) at 30° C. with vigorous aeration and spotted on agar plates containing 100 mM or 0.1 mM KC1. In part B, aliquots of cultures were spotted on agar plates containing clofilium (100 μM) or dofetilide (1 μM). Plates were scored after a 48-hour incubation at 30° C. 
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     The following definitions apply to the terms as used throughout this specification, unless otherwise limited in specific instances. 
     The terms &#34;deficient&#34; or &#34;deficiency&#34; as used with respect to a gene refers to an allele altered (e.g., by homologous recombination, resulting in the insertion of foreign sequences) such that either no product or only an inoperative fragment of the wild-type product can be expressed. A &#34;deficient&#34; allele within this definition may also comprise a gene deletion, wherein the gene has been deleted in toto; a gene disruption, wherein the gene is interrupted by another gene or nucleic acid sequence; a partial deletion, wherein one or more bases are deleted; a substitution, wherein one or more bases are replaced by other bases; and other such mutations as will be understood by persons having ordinary skill in the art. Such deletions, disruptions, and substitutions may take place in, for example, the coding region, a promoter, or an enhancer. 
     The term &#34;modified&#34; as used with respect to a cell refers to a cell in which the wild-type genome has been altered by addition of one or more heterologous genes, a defidency in one or more wild-type genes, or a combination thereof. Such modifications may be carried out by transformation and homologous recombination through techniques well understood by those having ordinary skill in the art. 
     The term &#34;a minK protein&#34; refers to a protein having at least the smallest portion of the full-length wild-type minK protein that can result in measurable potassium ion transport in Saccharomyces cerevisiae. Human minK protein is preferred. Exemplary methods for such measurement of potassium ion transport are described herein. Proteins having residues 41 to 72 of FIG. 2 are preferred for the minK protein. 
     The term &#34;a functional derivative or mutant thereof&#34; as used with respect to a protein refers to a protein differing from the subject protein by one or more amino acid residues but still having the biochemical function of the protein and greater than about 90% sequence homology. In the case of the minK protein, a &#34;functional derivative or mutant thereof&#34; refers to such proteins that have potassium transport activity but do not have the identical amino acid sequence shown in FIG. 2. Such derivatives and mutants may include proteins that differ from the wild-type protein by amino acid substitutions, deletions, disruptions, and the like. Such differences may be accomplished by genetic means, using such techniques as site-directed mutagenesis or mutagenic PCR prior to translation, or by chemical means, using proteases and/or ligases after translation. 
     The yeast cell of the present invention begins with a yeast strain having deficient alleles in the TRK1 and TRK2 genes required for potassium uptake. The modified alleles are genetically stable and recessive, so they can be complemented with activities encoded by heterologous genes introduced into the strain. 
     Biosynthetic marker genes (e.g., HIS3 and TRP1) may be inserted into the loci for the wild-type potassium uptake genes. Such modified alleles may then be transformed into yeast to replace the wild-type loci by homologous recombination. The modified alleles are readily detected by scoring for the presence of the biosynthetic marker. The markers inserted into the transporter loci also provide a simple means of transferring these mutations into other genetic backgrounds. 
     A strain deficient in one potassium uptake gene (e.g., TRK1) may be crossed with a strain of opposite mating type deficient in another potassium uptake gene (e.g., TRK2). Progeny bearing both genetic deficiencies may be identified by scoring for the presence of both markers. 
     A variety of potassium ion channels may be introduced into this strain to assess whether these channels can complement the growth defect on potassium-deficient media. Alternatively, the strain may be used to screen gene libraries (e.g., human cDNA libraries) for clones that complement the growth defect. This analysis may reveal potassium ion channels that have been described physiologically but have not yet been cloned. Each application results in a strain expressing a foreign potassium ion channel, useful in a screen for modulators of the channel. 
     A yeast strain expressing a potassium ion channel can be adapted to natural products screening. A simple screen design involving growth inhibition or potassium ion uptake in agar plates or in liquid culture may detect compounds that modulate channel function. For screening of activators of the potassium ion channel, the screen may include such modifications as metabolic inhibition of calcium, anoxic growth conditions, increased growth rate, or increased potassium ion uptake. 
     A test substance used in the process of this invention may be, for example, a synthetic compound or a natural product. Such natural products include extracts from plants, animals and microorganisms. 
     DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT 
     Knockout of the high affinity transporter 
     A mutation in the high affinity potassium transporter, TRK1, began with the isolation of the wild type gene from a yeast genomic library. Large portions of the 5&#39; and 3&#39; ends of the TRK1 coding region (FIG. 3, SEQ. ID. NO. 3) were amplified in polymerase chain reactions, radiolabeled and hybridized to colonies containing the yeast genomic library. Three clones contained the entire TRK1 locus (promoter and coding region) as determined by hybridization to both 5&#39; and 3&#39; fragments. These results were further confirmed by Southern blots and restriction mapping. 
     The TRK1 gene was subcloned into bacterial vectors, pUC19 and pSL1180. A 2350 bp deletion of the coding region was created by digestion with XbaI. Into this deletion was inserted the yeast biosynthetic gene HIS3. The mutant allele, trk1 ::HIS3, was used to transform yeast strains to histidine prototrophy. Transformants were verified by Southern blots. 
     Because TRK1 encodes the high affinity potassium ion transporter, the mutant strain should have a growth requirement for potassium. As expected, His +  transformants grew very poorly on media containing 100 μM potassium chloride. The growth defect was remediated by increasing the potassium concentration to 100 mM. 
     Knockout of the low affinity transporter 
     Oligonucleotides were used to produce portions of the TRK2 coding region (FIG. 4, SEQ. ID. NO. 5) corresponding to the 5&#39; (600 bp) and 3&#39; (800 bp) ends of the coding region by polymerase chain reaction (PCR) amplification of yeast genomic DNA. The fragments were assembled in pSL1180. The construct was linearized at the junction of the 5&#39; and 3&#39; coding fragments and religated with a fragment containing the yeast TRP1 gene to create trk2::TRP1. This construct lacks 1170 basepairs of the TRK2 coding region and was used to transform a yeast strain to tryptophan prototrophy. Transformants were verified by Southern blots. 
     Since the TRK2 locus encodes a low affinity potassium ion transporter, the mutant strain does not have a growth phenotype on potassium ion-deficient media. 
     Formation of the double mutant strain 
     The high and low affinity transporter mutations were constructed in yeast strains of opposite mating types to facilitate genetic analysis of the mutants and to obtain the double mutant (trk1-, trk2-) strain. Such a cross was carried out between the two strains (MATa, trk1 ::HIS3×MATa, trk2::TRP1). 
     The diploid strain grew vigorously on all media regardless of potassium concentration, indicating that the mutations are recessive. Recessive mutations are required for complementation with heterologous genes introduced into this strain. 
     In haploid, the modified alleles marked by the HIS3 and TRP1 biosynthetic marker genes were readily scored and segregated as expected for two unlinked genes. Both markers segregated 2+:2-, and their segregation was independent relative to each other. This result was anticipated, given that TRK1 maps to chromosome 10 and TRK2 maps to chromosome 11. The trkpheno-types (inviable on media with low concentrations of potassium) co-segregated with the appropriate biosynthetic markers, indicating that the introduced mutations mimic the phenotypes described in Rodriguez-Navarro, A. and Ramos, J., J. Bacteriol. 159:940-945 (1984); Ramos, J. et al., Arch. Microbiol. 143:88-93 (1985); Gaber, R., Styles, C. and Fink, G., Mol. Cell Biol. 8:2848-2859 (1988); and Ko, C. and Gaber, R., Genetics 125: 305-312 (1990). 
     Three phenotypes for potassium requirements were expected and observed from segregants of this cross, resulting from the following four genotypes: wild type, low affinity mutant, high affinity mutant, and double mutant (high and low affinity). Physical characterization of the modifications in the four segregants of a tetrad confirmed the segregation results. Southern blots and PCR amplification of the mutant loci with primers that flank the TRK genes produced the expected products. 
     Rescue of the mutant phenotype 
     The double mutant strain was transformed with a plasmid (pGAL) containing the wild type TRK1 gene, the heterologous test gene (HminK) or the vector alone. The HminK-transformed strain is a preferred embodiment of this invention and was deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852-1776 or Aug. 27, 1993 and assigned accession number ATCC 74,238. The strain is available upon issuance of a U.S. patent hereon and will be maintained for a period of at least 30 years after the date of deposit, and for a period of at least five years after the most recent request for a sample. 
     Transformants were diluted serially and spotted onto plates with either high (100 mM) or low (0.1 mM) concentrations of potassium chloride. Plates were incubated at 30° C. for 2 days. As shown in FIG. 7, strains containing either vector, TRK1, or HminK are able to grow at 100 mM potassium chloride, but only the TRK1 or HminK transformed strains grown at 0.1 mM potassium chloride. 
     Genetic and biochemical verification 
     Growth measurements of the trk mutants in either potassium-deficient or low pH media are consistent with the phenotypes reported in Gaber, R., Styles, C. and Fink, G., Mol. Cell Biol. 8:2848-2859 (1988) and Ko, C. and Gaber, R, Genetics 125:305-312 (1990). In media supplemented with potassium chloride, the mutant strains grew in a potassium-dependent manner (FIG. 5). 
     In another experiment, the double mutant was transformed with pGAL vector including either TRK1 or HminK as described above. The transformed strains were then separately challenged with clofilium (100 μM) and dofetilide (0.1 μM) at 100 mM and 0.1 mM of potassium chloride. As expected, clofilium blocked potassium uptake in the HminK strain but not in the TRK1 strain. 
     In addition, the HminK gene used in the transformation was sequenced. This analysis, which included sequencing of both strands, revealed a single nucleotide change resulting in the conversion of amino acid 38 from serine to glycine. This mutation is located in the N-terminus and does not appear to affect HminK function. 
     For further verification, mRNA transcripts were expressed in Xenopus oocytes. The expression products caused potassium ion currents that are blocked by clofilium (50 μM) and kinetically indistinguishable from HminK currents reported in the literature. This result is consistent with the recent report indicating that residues 41 to 72 define the pore of the protein and are sufficient to form channels in lipid bilayers. Ben Efraim et al., Biochemistry 32: 2371-2377 (1993). That report further indicates that the region encompassing residue 38 may not be functionally important. 
     Materials and Methods 
     Construction of the transporter mutant strain 
     A. trk1 deletion. TRK1 DNA sequences spanning nucleotides 181 to 4108 were synthesized by PCR amplification using the following oligonucleotides: 
     5&#39; CCGGATCCATGCATTTTAGAAGAACGATG 3&#39; (SEQ. ID. NO. 7) and 
     5&#39; ATCGGCATGCGTTGACGATGACGAAAGCAC 3&#39; (SEQ. ID. NO. 8). The product was digested with BamHI and SphI and cloned into pUC19. The plasmid was digested with XbaI to remove nucleotides 610 to 2964 from the coding region. The remaining vector and flanking regions of TRK1 was gel purified and ligated with a fragment containing the HIS3 gene, containing XbaI cohesive ends, to create a deletion/insertion mutation. This plasmid was digested with EcoRI and SphI and then used to transform a haploid yeast strain (MATa ade2-1, can1-100, his3-11,15, leu2-3,112trp1-1,ura3-1) to hisitidine prototrophy using the LiOAC procedure. To confirm the disruption of the TRK1 locus, His+ transformants were assessed by Southern blotting and growth on media lacking potassium. 
     B. trk2 deletion. Sequences corresponding to the 5&#39; and 3&#39; ends of the TRK2 coding region were obtained by PCR amplification of yeast genomic DNA. The following oligonucleotides were used to produce a portion of the 5&#39; end spanning nucleotides 1016 to 1639: 
     5&#39; GCGGATCCGTCGACTTCATTTCCGGGTTCT 3&#39; (SEQ. ID. NO. 9) and 
     5&#39; GCTAGGAGCTCCCGGGTTGGCGCTTACTTGAGAA 3&#39; (SEQ. ID. NO. 10). 
     The following oligonucleotides were used to produce a portion of the 3&#39; end spanning nucleotides 2729 to 3584: 
     5&#39; GTCTTAAACGCTACGGATTGGATTC 3&#39; (SEQ. ID. NO. 11) and 
     5&#39; GCTTCCCCCAAAACTTTGTTGC 3&#39; (SEQ. ID. NO. 12). 
     The 5&#39; and 3&#39; PCR-amplified products were digested with combinations of SalI and SacI, and SacI and BamHI: respectively. Fragments were gel purified and then ligated in a three-way ligation with vector pSL1180 (Pharmacia; Note that this vector was initially digested with HindIII and EcoRV, endfilled and religated to remove a portion of the polylinker. This modified vector was then digested with SalI and BamHI and gel-purified for the three-way ligation.) The three-way ligation product was digested with SacI and XmaI and ligated with the TRP1 gene, containing SacI and XmaI ends, to create an insertion/deletion mutation. This plasmid was digested with SalI and BamHI and then used to transform a hapioid yeast strain (MATa ade2-1, can1-100,. his3-11.15, leu2-3.112, trp1-1-1, ura3-1) to tryptophan prototrophy. Trp +  transformants were assessed by Southern blotting to confirm the disruption of the TRK2 locus. 
     C. To create the double mutant trk1D trk2D, a standard cross between transformants containing the trk1::HIS3 mutation and the trk2::TRP1 mutation was performed. The resulting diploid was induced to undergo meiosis and tetrads were dissected onto YPD media supplemented with 100 mM KCl. Complete tetrads were then assessed for segregation of the markers (His and Trp) and for growth on media containing either 100 mM, 10 mM, or 0.1 mM KCl. In tetratype tetrads, the four genotypes produced three phenotypes with respect to growth on potassium-deficient media. This is the expected result for the segregation of the trk1 and trk2 mutations which are unlinked genes. All colonies arising from spores that received both the His and Trp markers grow only on media containing 100 mM KCl, indicating that these colonies were defective in both K +  transporters. 
     Construction of Expression Plasmids 
     pGAL::HminK. The following oligonucleotides were used to amplify sequences encoding the Human HminK protein from HeLa cell genomic DNA: 
     5&#39; GCGAATTCAAAAAAAATGATCCTGTCTAACACCAC 3&#39; (SEQ. ID. NO. 13) and 
     5&#39; GCTCTAGATCATGGGGAAGGCTTCGTCTC 3&#39; (SEQ. ID. NO. 14). The PCR-amplified product was digested with EcoRI and XbaI gel pudfied and cloned into an identically digested pYES2 vector (Invitrogen). The plasmid was verified by standard restriction digests and the insert was analyzed by DNA sequencing. 
     pGAL::TRK1. The following oligonucleotides were used to amplify sequences encoding the yeast Trk1 protein from a plasmid containing the TRK1 gene (this plasmid was isolated from a yeast genomic library by hybridization with 5&#39; and 3&#39; DNA fragments unique to the TRK1 gene): 
     5&#39; CGGGATCCAAAAAATGCATTTTAGAAGAACGATGAG 3&#39; (SEQ. ID. NO. 15) and 
     5&#39; CCCGCTCGAGCGATGAGTGGGGATTTTGTC 3&#39; (SEQ. ID. NO. 16). The PCR-amplified product was digested with BamHI: and XhoI, gel purified and cloned into identically digested pYEUra3 vector (Clontech). The plasmid was verified by restriction digests and complements a trk1 deletion mutation when expressed in vivo. 
     Assay for growth on K +  deficient agar media 
     Cultures of K +  transporter mutant strains containing either pYES2 vector, pGAL::TRK1 or pGAL::HminK plasmids were grown in inducing media (2% galactose) at 30° C. with vigorous aeration. A. Serial dilutions of each culture were spotted onto agar plates containing either 100 mM or 0.1 mM. KCl. B. Serial dilutions of strains containing pGAL::TRK1 or pGAL::HminK plasmids were spotted onto agar plates containing 100 μM clofilium or 1 μM dofetilide at both KCl concentrations. All plates were incubated at 30° C. and scored after 2 days. 
     Assay for growth in the presence of inhibitors 
     Cultures of strains containing the pGAL::HminK plasmid or the pGAL::TRK1 plasmid were grown in inducing media (2% galactose) at 30° C. with vigorous aeration. Inhibitors were added to cultures over a range of concentrations. Samples were removed at various intervals and the optical density at 600 nm was determined. Growth measurements were normalized to values obtained for growth in the absence of drug and are plotted as Relative Growth versus concentration (FIG. 6). Similar cultures grown in inducing medium were embedded in agar and assessed for growth in presence of the compounds listed in Table 1. Plates were scored after a 48-hour incubation at 30° C.; &#34;+&#34; denotes growth inhibition. 
     
                       TABLE 1______________________________________                Inhibition in agar                      HminK   TRK1Compound  Activity         strain  strain______________________________________clofilium Class III AA (I.sub.KS and I.sub.KR)                      +       -dofetilide     Class III AA (I.sub.KR)                      -       -E-4031    Class III AA (I.sub.KR)                      -       -quinidine Class I AA (Na.sup.+  and K.sup.+)                      +       +tetrodotoxin     Na.sup.+  channel blocker                      -       -TEA Cl    nonselective K.sup.+  inhibitor                      +       -diltiazem Calcium entry blocker                      -       -______________________________________ (AA denotes antiarrhythmic; + indicates compound produced a zone on inhibition) 
    
     
         __________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 16(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 3707 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 1..3707(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:ATGCATTTTAGAAGAACGATGAGTAGAGTGCCCACATTGGCATCTCTT48MetHisPheArgArgThrMetSerArgValProThrLeuAlaSerLeu151015GAAATACGATATAAAAAATCTTTCGGCCATAAATTTCGTGATTTTATT96GluIleArgTyrLysLysSerPheGlyHisLysPheArgAspPheIle202530GCTCTATGTGGTCACTATTTTGCTCCAGTTAAAAAATATATCTTCCCC144AlaLeuCysGlyHisTyrPheAlaProValLysLysTyrIlePhePro354045AGTTTTATCGCGGTTCACTACTTCTACACGATATCCCTGACATTAATA192SerPheIleAlaValHisTyrPheTyrThrIleSerLeuThrLeuIle505560ACTTCAATCCTGCTATATCCCATTAAGAATACCAGATACATTGATACA240ThrSerIleLeuLeuTyrProIleLysAsnThrArgTyrIleAspThr65707580TTGTTTTTAGCAGCGGGCGCAGTTACACAAGGTGGCTTAAATACTGTG288LeuPheLeuAlaAlaGlyAlaValThrGlnGlyGlyLeuAsnThrVal859095GATATCAACAATCTAAGCTTATACCAACAAATTGTTCTGTATATCGTA336AspIleAsnAsnLeuSerLeuTyrGlnGlnIleValLeuTyrIleVal100105110TGCTGCATATCAACACCAATTGCAGTTCATAGTTGCTTGGCATTTGTA384CysCysIleSerThrProIleAlaValHisSerCysLeuAlaPheVal115120125CGGCTTTACTGGTTTGAGCGCTACTTCGATGGTATTAGAGACTCTTCT432ArgLeuTyrTrpPheGluArgTyrPheAspGlyIleArgAspSerSer130135140AGACGAAATTTTAAGATGAGAAGAACGAAAACAATCTTAGAAAGGGAA480ArgArgAsnPheLysMetArgArgThrLysThrIleLeuGluArgGlu145150155160CTAACAGCAAGAACCATGACCAAGAATAGAACAGGTACCCAAAGAACG528LeuThrAlaArgThrMetThrLysAsnArgThrGlyThrGlnArgThr165170175TCTTATCCTAGGAAACAAGCTAAAACAGATGATTTCCAAGAAAAATTG576SerTyrProArgLysGlnAlaLysThrAspAspPheGlnGluLysLeu180185190TTCAGCGGAGAAATGGTTAATAGAGATGAGCAGGACTCAGTTCACAGC624PheSerGlyGluMetValAsnArgAspGluGlnAspSerValHisSer195200205GACCAGAATTCTCATGACATTAGTAGGGACAGCAGCAATAATAATACG672AspGlnAsnSerHisAspIleSerArgAspSerSerAsnAsnAsnThr210215220AATCACAATGGTAGCAGTGGCAGTTTAGATGATTTCGTTAAGGAAGAC720AsnHisAsnGlySerSerGlySerLeuAspAspPheValLysGluAsp225230235240GAAACGGATGACAATGGAGAATATCAGGAGAACAACTCCTACTCGACG768GluThrAspAspAsnGlyGluTyrGlnGluAsnAsnSerTyrSerThr245250255GTAGGTAGTTCGTCTAACACAGTTGCAGACGAAAGTTTAAATCAGAAG816ValGlySerSerSerAsnThrValAlaAspGluSerLeuAsnGlnLys260265270CCCAAGCCAAGCAGTCTTCGGTTTGATGAGCCACACAGCAAACAAAGA864ProLysProSerSerLeuArgPheAspGluProHisSerLysGlnArg275280285CCCGCAAGAGTTCCCTCAGAGAAATTTGCAAAAAGAAGGGGTTCAAGA912ProAlaArgValProSerGluLysPheAlaLysArgArgGlySerArg290295300GATATTAGCCCAGCCGATATGTATCGATCCATTATGATGCTACAAGGT960AspIleSerProAlaAspMetTyrArgSerIleMetMetLeuGlnGly305310315320AAGCATGAAGCAACTGCTGAAGATGAAGGTCCCCCTTTAGTCATCGGG1008LysHisGluAlaThrAlaGluAspGluGlyProProLeuValIleGly325330335TCCCCTGCGGATGGCACAAGATATAAAAGTAATGTCAATAAGCTAAAG1056SerProAlaAspGlyThrArgTyrLysSerAsnValAsnLysLeuLys340345350AAGGCCACCGGCATAAATGGTAACAAAATCAAGATTCGAGATAAGGGA1104LysAlaThrGlyIleAsnGlyAsnLysIleLysIleArgAspLysGly355360365AATGAAAGTAACACTGATCAAAATTCCGTGTCAAGTGAAGCAAACAGT1152AsnGluSerAsnThrAspGlnAsnSerValSerSerGluAlaAsnSer370375380ACGGCGAGCGTTTCGGACGAAAGCTCGTTACACACAAATTTTGGTAAC1200ThrAlaSerValSerAspGluSerSerLeuHisThrAsnPheGlyAsn385390395400AAAGTACCTTCATTAAGAACAAATACTCATAGATCAAATTCGGGCCCG1248LysValProSerLeuArgThrAsnThrHisArgSerAsnSerGlyPro405410415ATAGCCATTACTGATAACGCAGAAACAGACAAAAAGCATGGGCCATCA1296IleAlaIleThrAspAsnAlaGluThrAspLysLysHisGlyProSer420425430ATTCAATTCGATATAACTAAACCTCCTAGAAAAATTTCAAAAAGAGTT1344IleGlnPheAspIleThrLysProProArgLysIleSerLysArgVal435440445TCAACCTTCGATGATTTGAACCCAAAATCTTCCGTTCTTTATCGAAAA1392SerThrPheAspAspLeuAsnProLysSerSerValLeuTyrArgLys450455460AAAGCATCGAAGAAGTACCTCATGAAACATTTTCCTAAAGCGCGGCGA1440LysAlaSerLysLysTyrLeuMetLysHisPheProLysAlaArgArg465470475480ATACGGCAACAAATTAAGAGAAGGCTTTCTACTGGTTCAATTGAGAAA1488IleArgGlnGlnIleLysArgArgLeuSerThrGlySerIleGluLys485490495AACAGCAGTAACAATGTTTCAGATAGAAAACCTATTACTGATATGGAT1536AsnSerSerAsnAsnValSerAspArgLysProIleThrAspMetAsp500505510GATGATGATGATGACGATGACAACGACGGCGATAACAACGAAGAATAC1584AspAspAspAspAspAspAspAsnAspGlyAspAsnAsnGluGluTyr515520525TTTGCTGACAACGAAAGCGGCGATGAAGATGAACGAGTACAGCAGTCT1632PheAlaAspAsnGluSerGlyAspGluAspGluArgValGlnGlnSer530535540GAACCACATTCTGATTCAGAACTCAAATCGCACCAACAACAGCAAGAA1680GluProHisSerAspSerGluLeuLysSerHisGlnGlnGlnGlnGlu545550555560AAACACCAACTGCAGCAGAACCTGCACCGCATGTATAAAACCAAATCA1728LysHisGlnLeuGlnGlnAsnLeuHisArgMetTyrLysThrLysSer565570575TTTGATGATAATCGTTCAAGAGCAGTTCCTATGGAACGTTCCAGGACC1776PheAspAspAsnArgSerArgAlaValProMetGluArgSerArgThr580585590ATCGATATGGCAGAGGCTAAGGATCTAAATGAGCTCGCAAGGACGCCT1824IleAspMetAlaGluAlaLysAspLeuAsnGluLeuAlaArgThrPro595600605GATTTTCAAAAAATGGTCTATCAAAATTGGAAAGCCCATCATAGAAAA1872AspPheGlnLysMetValTyrGlnAsnTrpLysAlaHisHisArgLys610615620AAACCGAACTTTAGGAAGAGGGGATGGAATAACAAGATATTTGAACAT1920LysProAsnPheArgLysArgGlyTrpAsnAsnLysIlePheGluHis625630635640GGTCCCTATGCATCTGACAGCGATCGCAATTATCCTGATAATAGTAAT1968GlyProTyrAlaSerAspSerAspArgAsnTyrProAspAsnSerAsn645650655ACTGGAAACAGTATTCTTCATTACGCAGAGTCTATTTTACATCATGAT2016ThrGlyAsnSerIleLeuHisTyrAlaGluSerIleLeuHisHisAsp660665670GGCTCTCATAAAAATGGAAGCGAAGAAGCCTCTTCCGACTCTAATGAG2064GlySerHisLysAsnGlySerGluGluAlaSerSerAspSerAsnGlu675680685AATATCTATTCCACGAATGGAGGAAGCGACCACAATGGTCTTAACAAC2112AsnIleTyrSerThrAsnGlyGlySerAspHisAsnGlyLeuAsnAsn690695700TATCCTACTTACAACGACGATGAAGAAGGCTATTATGGTTTACATTTC2160TyrProThrTyrAsnAspAspGluGluGlyTyrTyrGlyLeuHisPhe705710715720GATACCGATTATGACCTAGATCCTCGTCATGATTTATCTAAAGGCAGT2208AspThrAspTyrAspLeuAspProArgHisAspLeuSerLysGlySer725730735GGTAAAACGTATCTATCATGGCAACCAACTATTGGACGTAACTCAAAC2256GlyLysThrTyrLeuSerTrpGlnProThrIleGlyArgAsnSerAsn740745750TTCCTTGGATTAACAAGAGCCCAGAAAGATGAATTAGGTGGTGTCGAG2304PheLeuGlyLeuThrArgAlaGlnLysAspGluLeuGlyGlyValGlu755760765TACAGAGCAATCAAACTTTTATGCACCATATTGGTTGTCTACTACGTT2352TyrArgAlaIleLysLeuLeuCysThrIleLeuValValTyrTyrVal770775780GGATGGCATATTGTTGCTTTTGTTATGTTAGTACCTTGGATTATTTTG2400GlyTrpHisIleValAlaPheValMetLeuValProTrpIleIleLeu785790795800AAAAAGCATTATAGTGAAGTTGTTAGAGATGATGGTGTTTCACCTACA2448LysLysHisTyrSerGluValValArgAspAspGlyValSerProThr805810815TGGTGGGGATTTTGGACAGCAATGAGTGCATTTAATGATTTAGGTTTG2496TrpTrpGlyPheTrpThrAlaMetSerAlaPheAsnAspLeuGlyLeu820825830ACATTAACTCCAAATTCAATGATGTCGTTTAACAAAGCTGTATACCCA2544ThrLeuThrProAsnSerMetMetSerPheAsnLysAlaValTyrPro835840845TTGATCGTTATGATTTGGTTTATCATTATCGGAAATACAGGGTTTCCC2592LeuIleValMetIleTrpPheIleIleIleGlyAsnThrGlyPhePro850855860ATCCTTCTTAGATGCATCATTTGGATAATGTTTAAAATTTCTCCTGAT2640IleLeuLeuArgCysIleIleTrpIleMetPheLysIleSerProAsp865870875880TTATCACAGATGAGAGAAAGTTTAGGTTTTCTCTTAGACCATCCACGT2688LeuSerGlnMetArgGluSerLeuGlyPheLeuLeuAspHisProArg885890895CGTTGTTTCACCTTGCTATTTCCTAAGGCAGCTACATGGTGGCTACTT2736ArgCysPheThrLeuLeuPheProLysAlaAlaThrTrpTrpLeuLeu900905910TTAACGCTTGCAGGATTGAATATAACTGATTGGATTTTATTTATTATT2784LeuThrLeuAlaGlyLeuAsnIleThrAspTrpIleLeuPheIleIle915920925CTAGATTTTGGCTCAACAGTTGTGAAATCATTATCGAAAGGCTATAGA2832LeuAspPheGlySerThrValValLysSerLeuSerLysGlyTyrArg930935940GTCCTTGTCGGCCTGTTTCAATCTGTTAGCACAAGAACTGCTGGATTC2880ValLeuValGlyLeuPheGlnSerValSerThrArgThrAlaGlyPhe945950955960AGCGTTGTCGATTTAAGTCAACTGCATCCTTCTATCCAAGTCTCCTAT2928SerValValAspLeuSerGlnLeuHisProSerIleGlnValSerTyr965970975ATGCTAATGATGTATGTCTCCGTATTACCATTGGCCATCTCTATTCGA2976MetLeuMetMetTyrValSerValLeuProLeuAlaIleSerIleArg980985990CGGACAAATGTTTACGAGGAGCAATCTTTAGGACTATATGGAGATATG3024ArgThrAsnValTyrGluGluGlnSerLeuGlyLeuTyrGlyAspMet99510001005GGGGGAGAACCAGAAGATACGGATACTGAAGACGATGGTAACGATGAA3072GlyGlyGluProGluAspThrAspThrGluAspAspGlyAsnAspGlu101010151020GATGACGACGAGGAAAACGAGAGTCACGAAGGTCAAAGTAGTCAAAGA3120AspAspAspGluGluAsnGluSerHisGluGlyGlnSerSerGlnArg1025103010351040AGTAGTTCGAACAACAACAACAATAACAACAGGAAAAAGAAAAAGAAA3168SerSerSerAsnAsnAsnAsnAsnAsnAsnArgLysLysLysLysLys104510501055AAGAAAACTGAAAATCCAAATGAAATATCTACAAAATCCTTTATCGGT3216LysLysThrGluAsnProAsnGluIleSerThrLysSerPheIleGly106010651070GCCCATTTAAGGAAACAGCTTTCATTTGACTTGTGGTTTCTATTTTTA3264AlaHisLeuArgLysGlnLeuSerPheAspLeuTrpPheLeuPheLeu107510801085GGGTTATTTATCATTTGCATTTGTGAAGGGGACAAGATAAAGGACGTA3312GlyLeuPheIleIleCysIleCysGluGlyAspLysIleLysAspVal109010951100CAAGAACCAAACTTTAATATATTTGCAATTCTTTTTGAAATTGTTAGC3360GlnGluProAsnPheAsnIlePheAlaIleLeuPheGluIleValSer1105111011151120GCTTACGGTACAGTTGGGCTATCGCTAGGTTATCCGGACACCAACCAA3408AlaTyrGlyThrValGlyLeuSerLeuGlyTyrProAspThrAsnGln112511301135TCGTTTTCAAGACAGTTTACTACATTATCTAAGTTGGTGATCATAGCT3456SerPheSerArgGlnPheThrThrLeuSerLysLeuValIleIleAla114011451150ATGCTGATCAGAGGCAAGAATAGAGGTCTACCATACTCACTGGATCGT3504MetLeuIleArgGlyLysAsnArgGlyLeuProTyrSerLeuAspArg115511601165GCAATTATCTTGCCTAGTGATAGACTTGAACATATTGACCACCTTGAG3552AlaIleIleLeuProSerAspArgLeuGluHisIleAspHisLeuGlu117011751180GGCATGAAATTGAAGAGACAGGCTAGAACCAATACAGAAGACCCAATG3600GlyMetLysLeuLysArgGlnAlaArgThrAsnThrGluAspProMet1185119011951200ACGGAACATTTCAAGAGAAGTTTCACTGATGTGAAACATCGTTGGGGA3648ThrGluHisPheLysArgSerPheThrAspValLysHisArgTrpGly120512101215GCTCTTAAGCGTAAGACCACACATTCCCGAAATCCTAAAAGGAGCAGC3696AlaLeuLysArgLysThrThrHisSerArgAsnProLysArgSerSer122012251230ACAACGCTCTA3707ThrThrLeu123(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1235 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:MetHisPheArgArgThrMetSerArgValProThrLeuAlaSerLeu151015GluIleArgTyrLysLysSerPheGlyHisLysPheArgAspPheIle202530AlaLeuCysGlyHisTyrPheAlaProValLysLysTyrIlePhePro354045SerPheIleAlaValHisTyrPheTyrThrIleSerLeuThrLeuIle505560ThrSerIleLeuLeuTyrProIleLysAsnThrArgTyrIleAspThr65707580LeuPheLeuAlaAlaGlyAlaValThrGlnGlyGlyLeuAsnThrVal859095AspIleAsnAsnLeuSerLeuTyrGlnGlnIleValLeuTyrIleVal100105110CysCysIleSerThrProIleAlaValHisSerCysLeuAlaPheVal115120125ArgLeuTyrTrpPheGluArgTyrPheAspGlyIleArgAspSerSer130135140ArgArgAsnPheLysMetArgArgThrLysThrIleLeuGluArgGlu145150155160LeuThrAlaArgThrMetThrLysAsnArgThrGlyThrGlnArgThr165170175SerTyrProArgLysGlnAlaLysThrAspAspPheGlnGluLysLeu180185190PheSerGlyGluMetValAsnArgAspGluGlnAspSerValHisSer195200205AspGlnAsnSerHisAspIleSerArgAspSerSerAsnAsnAsnThr210215220AsnHisAsnGlySerSerGlySerLeuAspAspPheValLysGluAsp225230235240GluThrAspAspAsnGlyGluTyrGlnGluAsnAsnSerTyrSerThr245250255ValGlySerSerSerAsnThrValAlaAspGluSerLeuAsnGlnLys260265270ProLysProSerSerLeuArgPheAspGluProHisSerLysGlnArg275280285ProAlaArgValProSerGluLysPheAlaLysArgArgGlySerArg290295300AspIleSerProAlaAspMetTyrArgSerIleMetMetLeuGlnGly305310315320LysHisGluAlaThrAlaGluAspGluGlyProProLeuValIleGly325330335SerProAlaAspGlyThrArgTyrLysSerAsnValAsnLysLeuLys340345350LysAlaThrGlyIleAsnGlyAsnLysIleLysIleArgAspLysGly355360365AsnGluSerAsnThrAspGlnAsnSerValSerSerGluAlaAsnSer370375380ThrAlaSerValSerAspGluSerSerLeuHisThrAsnPheGlyAsn385390395400LysValProSerLeuArgThrAsnThrHisArgSerAsnSerGlyPro405410415IleAlaIleThrAspAsnAlaGluThrAspLysLysHisGlyProSer420425430IleGlnPheAspIleThrLysProProArgLysIleSerLysArgVal435440445SerThrPheAspAspLeuAsnProLysSerSerValLeuTyrArgLys450455460LysAlaSerLysLysTyrLeuMetLysHisPheProLysAlaArgArg465470475480IleArgGlnGlnIleLysArgArgLeuSerThrGlySerIleGluLys485490495AsnSerSerAsnAsnValSerAspArgLysProIleThrAspMetAsp500505510AspAspAspAspAspAspAspAsnAspGlyAspAsnAsnGluGluTyr515520525PheAlaAspAsnGluSerGlyAspGluAspGluArgValGlnGlnSer530535540GluProHisSerAspSerGluLeuLysSerHisGlnGlnGlnGlnGlu545550555560LysHisGlnLeuGlnGlnAsnLeuHisArgMetTyrLysThrLysSer565570575PheAspAspAsnArgSerArgAlaValProMetGluArgSerArgThr580585590IleAspMetAlaGluAlaLysAspLeuAsnGluLeuAlaArgThrPro595600605AspPheGlnLysMetValTyrGlnAsnTrpLysAlaHisHisArgLys610615620LysProAsnPheArgLysArgGlyTrpAsnAsnLysIlePheGluHis625630635640GlyProTyrAlaSerAspSerAspArgAsnTyrProAspAsnSerAsn645650655ThrGlyAsnSerIleLeuHisTyrAlaGluSerIleLeuHisHisAsp660665670GlySerHisLysAsnGlySerGluGluAlaSerSerAspSerAsnGlu675680685AsnIleTyrSerThrAsnGlyGlySerAspHisAsnGlyLeuAsnAsn690695700TyrProThrTyrAsnAspAspGluGluGlyTyrTyrGlyLeuHisPhe705710715720AspThrAspTyrAspLeuAspProArgHisAspLeuSerLysGlySer725730735GlyLysThrTyrLeuSerTrpGlnProThrIleGlyArgAsnSerAsn740745750PheLeuGlyLeuThrArgAlaGlnLysAspGluLeuGlyGlyValGlu755760765TyrArgAlaIleLysLeuLeuCysThrIleLeuValValTyrTyrVal770775780GlyTrpHisIleValAlaPheValMetLeuValProTrpIleIleLeu785790795800LysLysHisTyrSerGluValValArgAspAspGlyValSerProThr805810815TrpTrpGlyPheTrpThrAlaMetSerAlaPheAsnAspLeuGlyLeu820825830ThrLeuThrProAsnSerMetMetSerPheAsnLysAlaValTyrPro835840845LeuIleValMetIleTrpPheIleIleIleGlyAsnThrGlyPhePro850855860IleLeuLeuArgCysIleIleTrpIleMetPheLysIleSerProAsp865870875880LeuSerGlnMetArgGluSerLeuGlyPheLeuLeuAspHisProArg885890895ArgCysPheThrLeuLeuPheProLysAlaAlaThrTrpTrpLeuLeu900905910LeuThrLeuAlaGlyLeuAsnIleThrAspTrpIleLeuPheIleIle915920925LeuAspPheGlySerThrValValLysSerLeuSerLysGlyTyrArg930935940ValLeuValGlyLeuPheGlnSerValSerThrArgThrAlaGlyPhe945950955960SerValValAspLeuSerGlnLeuHisProSerIleGlnValSerTyr965970975MetLeuMetMetTyrValSerValLeuProLeuAlaIleSerIleArg980985990ArgThrAsnValTyrGluGluGlnSerLeuGlyLeuTyrGlyAspMet99510001005GlyGlyGluProGluAspThrAspThrGluAspAspGlyAsnAspGlu101010151020AspAspAspGluGluAsnGluSerHisGluGlyGlnSerSerGlnArg1025103010351040SerSerSerAsnAsnAsnAsnAsnAsnAsnArgLysLysLysLysLys104510501055LysLysThrGluAsnProAsnGluIleSerThrLysSerPheIleGly106010651070AlaHisLeuArgLysGlnLeuSerPheAspLeuTrpPheLeuPheLeu107510801085GlyLeuPheIleIleCysIleCysGluGlyAspLysIleLysAspVal109010951100GlnGluProAsnPheAsnIlePheAlaIleLeuPheGluIleValSer1105111011151120AlaTyrGlyThrValGlyLeuSerLeuGlyTyrProAspThrAsnGln112511301135SerPheSerArgGlnPheThrThrLeuSerLysLeuValIleIleAla114011451150MetLeuIleArgGlyLysAsnArgGlyLeuProTyrSerLeuAspArg115511601165AlaIleIleLeuProSerAspArgLeuGluHisIleAspHisLeuGlu117011751180GlyMetLysLeuLysArgGlnAlaArgThrAsnThrGluAspProMet1185119011951200ThrGluHisPheLysArgSerPheThrAspValLysHisArgTrpGly120512101215AlaLeuLysArgLysThrThrHisSerArgAsnProLysArgSerSer122012251230ThrThrLeu1235(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 2669 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 1..2669(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:ATGCCAACAGCTAAGAGGACGTCATCCAGGGCTTCGTTGGCACTGCCC48MetProThrAlaLysArgThrSerSerArgAlaSerLeuAlaLeuPro151015TTCCAGTTACGGTTGGTGCACAAGAAATCATGGGGCCATCGGCTAAGA96PheGlnLeuArgLeuValHisLysLysSerTrpGlyHisArgLeuArg202530GACTTCATTTCCGGGTTCTTAAAATCATGCAGACCCATTGCTAAATAC144AspPheIleSerGlyPheLeuLysSerCysArgProIleAlaLysTyr354045GTTTTCCCCAACTTCATCGTGGTGCACTATATCTACCTGATCACGCTG192ValPheProAsnPheIleValValHisTyrIleTyrLeuIleThrLeu505560TCGATTATCGGGTCCATTCTGTTATATCCGTGCAAGAACACGGCGTTC240SerIleIleGlySerIleLeuLeuTyrProCysLysAsnThrAlaPhe65707580ATCGATGTGCTATTTCTGGCTGCTGGAGCGTCTACACAGGGCGGGCTG288IleAspValLeuPheLeuAlaAlaGlyAlaSerThrGlnGlyGlyLeu859095GCCACCAAGAGCACTAACGATTTCAACCTGTACCAGCAGATAGTGGTG336AlaThrLysSerThrAsnAspPheAsnLeuTyrGlnGlnIleValVal100105110TACGTCATTACATTGCTGTCCACGCCTATACTTATTCATGGGTTTTTG384TyrValIleThrLeuLeuSerThrProIleLeuIleHisGlyPheLeu115120125GCCTTTGTCAGGCTGTATTGGTTTGAAAGGTACTTCGACAACATTAGG432AlaPheValArgLeuTyrTrpPheGluArgTyrPheAspAsnIleArg130135140GATATCTCCAAACAGAATTTTAAACTAAGAAGGACCATGACGTTGCAA480AspIleSerLysGlnAsnPheLysLeuArgArgThrMetThrLeuGln145150155160CAAAGGGAACTATCGGGCAGCAGTGGCAATGCCGCTCGAAGTAGGAGT528GlnArgGluLeuSerGlySerSerGlyAsnAlaAlaArgSerArgSer165170175TTCAAGGACAACCTGTTCCGTGGGAAGTTTGTTTCCAGAGAAGACCCA576PheLysAspAsnLeuPheArgGlyLysPheValSerArgGluAspPro180185190CGACAATCCGCTTCAGATGTGCCGATGGACTCTCCTGACACGTCCGCA624ArgGlnSerAlaSerAspValProMetAspSerProAspThrSerAla195200205TTGTCCTCAATCTCACCGTTGAATGTTTCCTCCTCTAAGGAGGAATCC672LeuSerSerIleSerProLeuAsnValSerSerSerLysGluGluSer210215220AGTGACACGCAAAGCTCGCCTCCAAACTTCTCAAGTAAGCGCCAACCC720SerAspThrGlnSerSerProProAsnPheSerSerLysArgGlnPro225230235240TCAGACGTTGACCCAAGAGACATTTACAAATCGATAATGATGCTACAA768SerAspValAspProArgAspIleTyrLysSerIleMetMetLeuGln245250255AAACAACAAGAGAAGAGCAACGCAAACTCCACGGATTCTTTTTCGAGC816LysGlnGlnGluLysSerAsnAlaAsnSerThrAspSerPheSerSer260265270GAGACCAATGGACCCGCTTTCATTGTGCAGGAACGTCATGAGAGAAGA864GluThrAsnGlyProAlaPheIleValGlnGluArgHisGluArgArg275280285GCCCCCCACTGCTCACTGAAACGCCATTCTGTCCTGCCATCTTCTCAG912AlaProHisCysSerLeuLysArgHisSerValLeuProSerSerGln290295300GAATTGAACAAGCTAGCCCAGACGAAAAGTTTCCAGAAATTGCTTGGC960GluLeuAsnLysLeuAlaGlnThrLysSerPheGlnLysLeuLeuGly305310315320TTGCGGAGAGATGAAGGTGACCATGACTACTTTGACGGTGCTCCTCAC1008LeuArgArgAspGluGlyAspHisAspTyrPheAspGlyAlaProHis325330335AAATATATGGTCACCAAGAAGAAAAAAATATCTAGAACGCAATCATGT1056LysTyrMetValThrLysLysLysLysIleSerArgThrGlnSerCys340345350AACATCCCAACGTATACTGCTTCACCGAGTCCTAAAACCTCAGGCCAA1104AsnIleProThrTyrThrAlaSerProSerProLysThrSerGlyGln355360365GTAGTTGAAAATCATAGAAACTTGGCCAAGTCGGCGCCTTCATCTTTT1152ValValGluAsnHisArgAsnLeuAlaLysSerAlaProSerSerPhe370375380GTTGATGAGGAGATGAGCTTTTCACCGCAAGAGTCTTTGAATTTACAG1200ValAspGluGluMetSerPheSerProGlnGluSerLeuAsnLeuGln385390395400TTCCAAGCGCACCCGCCCAAACCAAAACGACGTGAAGGTGATATAGGC1248PheGlnAlaHisProProLysProLysArgArgGluGlyAspIleGly405410415CACCCCTTCACCAGAACAATGAGCACCAACTATCTATCGTGGCAGCCA1296HisProPheThrArgThrMetSerThrAsnTyrLeuSerTrpGlnPro420425430ACCTTTGGCAGAAACTCCGTCTTCATTGGACTCACAAAGCAACAAAAG1344ThrPheGlyArgAsnSerValPheIleGlyLeuThrLysGlnGlnLys435440445GAGGAACTCGGCGGTGTCGAATATCGTGCTTTGAGATTGCTGTGCTGC1392GluGluLeuGlyGlyValGluTyrArgAlaLeuArgLeuLeuCysCys450455460ATTCTCATGGTATACTACATCGGATTCAACATTTTGGCGTTTGTGACC1440IleLeuMetValTyrTyrIleGlyPheAsnIleLeuAlaPheValThr465470475480ATCGTTCCATGGGCCTGTACGAGGCACCACTACTCAGAGATTATTAGA1488IleValProTrpAlaCysThrArgHisHisTyrSerGluIleIleArg485490495CGAAATGGAGTTTCTCCAACCTGGTGGGGGTTTTTCACTGCAATGAGT1536ArgAsnGlyValSerProThrTrpTrpGlyPhePheThrAlaMetSer500505510GCATTCAGCAACTTGGGTCTGTCTTTGACCGCTGATTCAATGGTTTCC1584AlaPheSerAsnLeuGlyLeuSerLeuThrAlaAspSerMetValSer515520525TTTGATACTGCGCCGTATCCGCTGATTTTCATGATGTTCTTCATCATC1632PheAspThrAlaProTyrProLeuIlePheMetMetPhePheIleIle530535540ATAGGCAATACAGGCTTCCCAATTATGTTACGATTTATCATTTGGATC1680IleGlyAsnThrGlyPheProIleMetLeuArgPheIleIleTrpIle545550555560ATGTTCAAGACCTCGAGAGACCTATCTCAGTTTAAGGAAAGTCTTGGG1728MetPheLysThrSerArgAspLeuSerGlnPheLysGluSerLeuGly565570575TTTCTCTTGGATCATCCGCGCAGGTGTTTTACGTTGCTGTTCCCCAGC1776PheLeuLeuAspHisProArgArgCysPheThrLeuLeuPheProSer580585590GGCCCCACATGGTGGCTGTTTACAACTTTAGTCGTCTTAAACGCTACG1824GlyProThrTrpTrpLeuPheThrThrLeuValValLeuAsnAlaThr595600605GATTGGATTCTTTTCATAATTCTGGATTTCAACTCCGCTGTAGTAAGG1872AspTrpIleLeuPheIleIleLeuAspPheAsnSerAlaValValArg610615620CAGGTTGCTAAAGGTTATCGAGCTCTCATGGGCCTCTTCCAGTCTGTA1920GlnValAlaLysGlyTyrArgAlaLeuMetGlyLeuPheGlnSerVal625630635640TGCACAAGAACTGCTGGATTCAACGTTGTTGACTTAAGTAAATTACAC1968CysThrArgThrAlaGlyPheAsnValValAspLeuSerLysLeuHis645650655CCGTCCATTCAGGTGTCTTATATGCTAATGATGTACGTTTCGGTCCTG2016ProSerIleGlnValSerTyrMetLeuMetMetTyrValSerValLeu660665670CCGCTGGCGATTTCCATTAGAAGAACGAATGTTTATGAGGAGCAATCG2064ProLeuAlaIleSerIleArgArgThrAsnValTyrGluGluGlnSer675680685TTGGGACTATACGATAGTGGACAAGATGACGAAAATATCACCCACGAA2112LeuGlyLeuTyrAspSerGlyGlnAspAspGluAsnIleThrHisGlu690695700GACGATATAAAGGAAACAGACCATGATGGCGAATCCGAAGAGCGAGAC2160AspAspIleLysGluThrAspHisAspGlyGluSerGluGluArgAsp705710715720ACTGTATCTACAAAGTCCAAGCCGAAGAAACAGTCCCCAAAATCGTTT2208ThrValSerThrLysSerLysProLysLysGlnSerProLysSerPhe725730735GTTGGTGCTCATTTGAGGAGGCAACTCTCTTTTGATTTATGGTACCTA2256ValGlyAlaHisLeuArgArgGlnLeuSerPheAspLeuTrpTyrLeu740745750TTCCTTGGATTATTTATAATATGCATATGCGAGGGCAGAAAAATCGAA2304PheLeuGlyLeuPheIleIleCysIleCysGluGlyArgLysIleGlu755760765GACGTTAATAAACCTGATTTCAATGTCTTTGCTATATTGTTTGAAGTT2352AspValAsnLysProAspPheAsnValPheAlaIleLeuPheGluVal770775780GTTAGCGCTTATGGTACAGTGGGTTTGTCATTGGGTTACCCAAACACC2400ValSerAlaTyrGlyThrValGlyLeuSerLeuGlyTyrProAsnThr785790795800AACACATCACTATCTGCCCAGTTCACCGTATTATCGAAGCTAGTCATA2448AsnThrSerLeuSerAlaGlnPheThrValLeuSerLysLeuValIle805810815ATTGCCATGCTAATAAGAGGAAGAAATAGAGGTTTACCATACACTTTG2496IleAlaMetLeuIleArgGlyArgAsnArgGlyLeuProTyrThrLeu820825830GATCGTGCCATCATGCTGCCAAGTGACAAACTGGAACAAATTGATCGT2544AspArgAlaIleMetLeuProSerAspLysLeuGluGlnIleAspArg835840845TTACAAGATATGAAAGCTAAGGGTAAGTTGTTAGCCAAAGTTGGTGAG2592LeuGlnAspMetLysAlaLysGlyLysLeuLeuAlaLysValGlyGlu850855860GATCCAATGACTACTTACGTCAAAAAGAGATCCCACAAACTGAAAAAA2640AspProMetThrThrTyrValLysLysArgSerHisLysLeuLysLys865870875880ATAGCAACAAAGTTTTGGGGGAAGCATTA2669IleAlaThrLysPheTrpGlyLysHis885(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 889 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:MetProThrAlaLysArgThrSerSerArgAlaSerLeuAlaLeuPro151015PheGlnLeuArgLeuValHisLysLysSerTrpGlyHisArgLeuArg202530AspPheIleSerGlyPheLeuLysSerCysArgProIleAlaLysTyr354045ValPheProAsnPheIleValValHisTyrIleTyrLeuIleThrLeu505560SerIleIleGlySerIleLeuLeuTyrProCysLysAsnThrAlaPhe65707580IleAspValLeuPheLeuAlaAlaGlyAlaSerThrGlnGlyGlyLeu859095AlaThrLysSerThrAsnAspPheAsnLeuTyrGlnGlnIleValVal100105110TyrValIleThrLeuLeuSerThrProIleLeuIleHisGlyPheLeu115120125AlaPheValArgLeuTyrTrpPheGluArgTyrPheAspAsnIleArg130135140AspIleSerLysGlnAsnPheLysLeuArgArgThrMetThrLeuGln145150155160GlnArgGluLeuSerGlySerSerGlyAsnAlaAlaArgSerArgSer165170175PheLysAspAsnLeuPheArgGlyLysPheValSerArgGluAspPro180185190ArgGlnSerAlaSerAspValProMetAspSerProAspThrSerAla195200205LeuSerSerIleSerProLeuAsnValSerSerSerLysGluGluSer210215220SerAspThrGlnSerSerProProAsnPheSerSerLysArgGlnPro225230235240SerAspValAspProArgAspIleTyrLysSerIleMetMetLeuGln245250255LysGlnGlnGluLysSerAsnAlaAsnSerThrAspSerPheSerSer260265270GluThrAsnGlyProAlaPheIleValGlnGluArgHisGluArgArg275280285AlaProHisCysSerLeuLysArgHisSerValLeuProSerSerGln290295300GluLeuAsnLysLeuAlaGlnThrLysSerPheGlnLysLeuLeuGly305310315320LeuArgArgAspGluGlyAspHisAspTyrPheAspGlyAlaProHis325330335LysTyrMetValThrLysLysLysLysIleSerArgThrGlnSerCys340345350AsnIleProThrTyrThrAlaSerProSerProLysThrSerGlyGln355360365ValValGluAsnHisArgAsnLeuAlaLysSerAlaProSerSerPhe370375380ValAspGluGluMetSerPheSerProGlnGluSerLeuAsnLeuGln385390395400PheGlnAlaHisProProLysProLysArgArgGluGlyAspIleGly405410415HisProPheThrArgThrMetSerThrAsnTyrLeuSerTrpGlnPro420425430ThrPheGlyArgAsnSerValPheIleGlyLeuThrLysGlnGlnLys435440445GluGluLeuGlyGlyValGluTyrArgAlaLeuArgLeuLeuCysCys450455460IleLeuMetValTyrTyrIleGlyPheAsnIleLeuAlaPheValThr465470475480IleValProTrpAlaCysThrArgHisHisTyrSerGluIleIleArg485490495ArgAsnGlyValSerProThrTrpTrpGlyPhePheThrAlaMetSer500505510AlaPheSerAsnLeuGlyLeuSerLeuThrAlaAspSerMetValSer515520525PheAspThrAlaProTyrProLeuIlePheMetMetPhePheIleIle530535540IleGlyAsnThrGlyPheProIleMetLeuArgPheIleIleTrpIle545550555560MetPheLysThrSerArgAspLeuSerGlnPheLysGluSerLeuGly565570575PheLeuLeuAspHisProArgArgCysPheThrLeuLeuPheProSer580585590GlyProThrTrpTrpLeuPheThrThrLeuValValLeuAsnAlaThr595600605AspTrpIleLeuPheIleIleLeuAspPheAsnSerAlaValValArg610615620GlnValAlaLysGlyTyrArgAlaLeuMetGlyLeuPheGlnSerVal625630635640CysThrArgThrAlaGlyPheAsnValValAspLeuSerLysLeuHis645650655ProSerIleGlnValSerTyrMetLeuMetMetTyrValSerValLeu660665670ProLeuAlaIleSerIleArgArgThrAsnValTyrGluGluGlnSer675680685LeuGlyLeuTyrAspSerGlyGlnAspAspGluAsnIleThrHisGlu690695700AspAspIleLysGluThrAspHisAspGlyGluSerGluGluArgAsp705710715720ThrValSerThrLysSerLysProLysLysGlnSerProLysSerPhe725730735ValGlyAlaHisLeuArgArgGlnLeuSerPheAspLeuTrpTyrLeu740745750PheLeuGlyLeuPheIleIleCysIleCysGluGlyArgLysIleGlu755760765AspValAsnLysProAspPheAsnValPheAlaIleLeuPheGluVal770775780ValSerAlaTyrGlyThrValGlyLeuSerLeuGlyTyrProAsnThr785790795800AsnThrSerLeuSerAlaGlnPheThrValLeuSerLysLeuValIle805810815IleAlaMetLeuIleArgGlyArgAsnArgGlyLeuProTyrThrLeu820825830AspArgAlaIleMetLeuProSerAspLysLeuGluGlnIleAspArg835840845LeuGlnAspMetLysAlaLysGlyLysLeuLeuAlaLysValGlyGlu850855860AspProMetThrThrTyrValLysLysArgSerHisLysLeuLysLys865870875880IleAlaThrLysPheTrpGlyLysHis885(2) INFORMATION FOR SEQ ID NO:5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 398 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 1..398(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:ATGCCCAGGATGATCCTGTCTAACACCACAGCGGTGACGCCCTTTCTG48MetProArgMetIleLeuSerAsnThrThrAlaValThrProPheLeu151015ACCAAGCTGTGGCAGGAGACAGTTCAGCAGGGTGGCAACATGTCGGGC96ThrLysLeuTrpGlnGluThrValGlnGlnGlyGlyAsnMetSerGly202530CTGGCCCGCAGGTCCCCCCGCAGCAGTGACGGCAAGCTGGAGGCCCTC144LeuAlaArgArgSerProArgSerSerAspGlyLysLeuGluAlaLeu354045TACGTCCTCATGGTACTGGGATTCTTCGGCTTCTTCACCCTGGGCATC192TyrValLeuMetValLeuGlyPhePheGlyPhePheThrLeuGlyIle505560ATGCTGAGCTACATCCGCTCCAAGAAGCTGGAGCACTCGAACGACCCA240MetLeuSerTyrIleArgSerLysLysLeuGluHisSerAsnAspPro65707580TTCAACGTCTACATCGAGTCCGATGCCTGGCAAGAGAAGGACAAGGCC288PheAsnValTyrIleGluSerAspAlaTrpGlnGluLysAspLysAla859095TATGTCCAGGCCCGGGTCCTGGAGAGCTACAGGTCGTGCTATGTCGTT336TyrValGlnAlaArgValLeuGluSerTyrArgSerCysTyrValVal100105110GAAAACCATCTGGCCATAGAACAACCCAACACACACCTTCCTGAGACG384GluAsnHisLeuAlaIleGluGlnProAsnThrHisLeuProGluThr115120125AAGCCTTCCCCATG398LysProSerPro130(2) INFORMATION FOR SEQ ID NO:6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 132 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:MetProArgMetIleLeuSerAsnThrThrAlaValThrProPheLeu151015ThrLysLeuTrpGlnGluThrValGlnGlnGlyGlyAsnMetSerGly202530LeuAlaArgArgSerProArgSerSerAspGlyLysLeuGluAlaLeu354045TyrValLeuMetValLeuGlyPhePheGlyPhePheThrLeuGlyIle505560MetLeuSerTyrIleArgSerLysLysLeuGluHisSerAsnAspPro65707580PheAsnValTyrIleGluSerAspAlaTrpGlnGluLysAspLysAla859095TyrValGlnAlaArgValLeuGluSerTyrArgSerCysTyrValVal100105110GluAsnHisLeuAlaIleGluGlnProAsnThrHisLeuProGluThr115120125LysProSerPro130(2) INFORMATION FOR SEQ ID NO:7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 29 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:CCGGATCCATGCATTTTAGAAGAACGATG29(2) INFORMATION FOR SEQ ID NO:8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 30 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:ATCGGCATGCGTTGACGATGACGAAAGCAC30(2) INFORMATION FOR SEQ ID NO:9:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 30 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:GCGGATCCGTCGACTTCATTTCCGGGTTCT30(2) INFORMATION FOR SEQ ID NO:10:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 34 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:GCTAGGAGCTCCCGGGTTGGCGCTTACTTGAGAA34(2) INFORMATION FOR SEQ ID NO:11:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:GTCTTAAACGCTACGGATTGGATTC25(2) INFORMATION FOR SEQ ID NO:12:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:GCTTCCCCCAAAACTTTGTTGC22(2) INFORMATION FOR SEQ ID NO:13:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 35 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:GCGAATTCAAAAAAAATGATCCTGTCTAACACCAC35(2) INFORMATION FOR SEQ ID NO:14:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 29 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:GCTCTAGATCATGGGGAAGGCTTCGTCTC29(2) INFORMATION FOR SEQ ID NO:15:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 36 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:CGGGATCCAAAAAATGCATTTTAGAAGAACGATGAG36(2) INFORMATION FOR SEQ ID NO:16:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 30 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:CCCGCTCGAGCGATGAGTGGGGATTTTGTC30__________________________________________________________________________